|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 50, 641-650, April 2009 Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL*
* Department of Internal Medicine, Endocrinology Division, University of Kentucky Medical Center, Lexington, KY 40536 * This work was funded by National Institutes of Health Grant RO1HL-071098 to N.R.W. The authors thank Kathy Forrest and William Bailey for excellent technical assistance. Published, JLR Papers in Press, December 3, 2008.
1 To whom correspondence should be addressed. e-mail: nrwebb1{at}uky.edu We previously reported that LDL modified by group V secretory phospholipase A2 (GV-LDL) promotes macrophage foam cell formation through a mechanism independent of scavenger receptors SR-A and CD36, and dependent on cellular proteoglycans. This study investigates the role of syndecans, a family of cell surface proteoglycans known to mediate endocytosis through macropinocytosis, in macrophage uptake of GV-LDL. LY 294002, a phosphatidylinositol 3-kinase inhibitor, significantly reduced internalization of 125I-labeled GV-LDL in J-774 macrophages, consistent with a macropinocytic uptake pathway. Using small, interfering RNA-directed gene silencing, we demonstrated a direct relationship between 125I-labeled GV-LDL binding and the level of syndecan-3 and syndecan-4 expression in J-774 cells. However, 125I-labeled GV-LDL uptake was significantly reduced only when syndecan-4 expression was suppressed. Peritoneal macrophages from syndecan-4-deficient mice exhibited markedly reduced uptake of fluorescently labeled GV-LDL compared with wild-type cells. Furthermore, cholesteryl ester accumulation induced by GV-LDL was dependent on syndecan-4 expression. Syndecan-4 expression and GV-LDL binding were significantly increased in J-774 cells treated with lipopolysaccharide, suggesting that GV-LDL uptake via this pathway may be enhanced during inflammation. Taken together, our data point to a novel role for syndecan-4 in mediating the uptake of GV-LDL, a process implicated in atherosclerotic lesion progression.
Supplementary key words atherosclerosis foam cells macropinocytosis proteoglycan lipoprotein modification Abbreviations: apoB-100, apolipoprotein B-100; CE, cholesteryl ester; ECM, extracellular matrix; GAG, glucosaminoglycan; GV, group V; HSPG, heparan sulfate proteoglycan; LPS, lipopolysaccharide; MPM, mouse peritoneal macrophage; ox-LDL, oxidized LDL; PI, phosphatidylinositol; sPLA2, secretory phospholipase A2
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||